Credit:
Alternating therapies shows a simulation of alternating therapy enzalutamide-cabazitaxel, at treatment start, six weeks, and 12 weeks (L-R), which almost got rid of the cancer, and succeeds in eliminating it when given as a longer treatment at a higher dose.